2024
Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis
Moledina D, Obeid W, Smith R, Rosales I, Sise M, Moeckel G, Kashgarian M, Kuperman M, Campbell K, Lefferts S, Meliambro K, Bitzer M, Perazella M, Luciano R, Pober J, Cantley L, Colvin R, Wilson F, Parikh C. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. Journal Of Clinical Investigation 2024, 134: e180583. PMID: 38488004, PMCID: PMC10940080, DOI: 10.1172/jci180583.Peer-Reviewed Original Research
2011
Risk of Poor Outcomes with Novel and Traditional Biomarkers at Clinical AKI Diagnosis
Hall IE, Coca SG, Perazella MA, Eko UU, Luciano RL, Peter PR, Han WK, Parikh CR. Risk of Poor Outcomes with Novel and Traditional Biomarkers at Clinical AKI Diagnosis. Clinical Journal Of The American Society Of Nephrology 2011, 6: 2740-2749. PMID: 22034509, PMCID: PMC3255362, DOI: 10.2215/cjn.04960511.Peer-Reviewed Original ResearchConceptsKidney injury molecule-1Neutrophil gelatinase-associated lipocalinAcute kidney injuryAcute tubular necrosisMicroscopy scorePrimary outcomeIL-18Prognostic utilityClinical assessmentInjury molecule-1Peak serum creatinineProspective cohort studyGelatinase-associated lipocalinFirst dayUrine protein biomarkersProtein biomarker concentrationsAKI criteriaAKI diagnosisAKI stageBaseline GFRHospital deathKidney injuryCohort studySerum creatinineTubular necrosis